AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 102 min read$MDT

Jim Cramer Calls Medtronic (MDT) a “Quandary” as Growth Surges and Diabetes Exit Nears

Medtronic (MDT) reported Q1 2027 revenue of $9.8B, up 13.7% organically, and raised full-year guidance. Jim Cramer called the company a 'quandary' due to strong growth and the planned separation of its diabetes division. The stock has not moved despite the positive results. Medtronic also announced investments in surgical robotics.

Original reporting
yahoo.com
Published Sep 10, 2026, 1:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 2:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Jim Cramer Calls Medtronic (MDT) a “Quandary” as Growth Surges and Diabetes Exit Nears — source image
Source · yahoo.com
Decision brief

The 30-second read

$MDTBullishMed
01

Why it matters

The earnings beat and guidance raise provide fresh data for traders; the commentary adds qualitative support but does not change the core numbers.

02

Market read

Medtronic's earnings and guidance lift are the primary market‑moving elements; sector peers may be impacted.

03

What to watch

One‑time $570M boost from an extra fiscal week may overstate organic growth momentum.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

Jim Cramer highlighted Medtronic's strong Q1 results and upcoming diabetes division spin‑off on Mad Money.

Company-level read

Ticker impact

$MDTBullishHigh confidence
Context

Medtronic reported Q1 2027 revenue of $9.8B, up 13.7% organic, and raised full-year organic revenue growth guidance to 7.25%-7.75%.

Expected impact

Potential upside as investors re‑price higher growth expectations.

Evidence & confidence

Guidance lift and solid organic growth are material new data; market typically reacts positively to such earnings surprises.

Market effects

Sector

Positive signal for the broader medical‑device sector, especially cardiovascular and surgical robotics peers.

Regional

U.S. healthcare stocks may see modest gains following the upbeat guidance.

Global

Limited to investors tracking large‑cap medtech names worldwide.

Counterpoint

What could challenge this read

Margin expansion is modest and diabetes division exit could reduce long‑term revenue base.

Key entities

  • company
    Medtronic plc

    Medical device manufacturer reporting Q1 2027 results.

  • company
    Cornerstone Robotics

    Partner for Sentire surgical system distribution.

Read at source← All news

Related articles

SEP 9
$MDTHighAI 8/10

Medtronic Raises 2027 Outlook as Broad-Based Growth Gains Momentum

Medtronic (MDT) raised its 2027 outlook after Q1 earnings and revenue beat expectations, with adjusted EPS at $1.45 (+15.1% YoY) and revenue at $9.76B (+13.7% YoY). The company increased revenue and EPS guidance, citing strong performance across major businesses. Acquisitions in neurovascular and pain therapies are expected to contribute over $150M in revenue for 2027.

finance.yahoo.com2 min
SEP 9
$MDTMed

Wall Street Isn't Talking About High-Yield Medtronic Stock -- Here's Why It Should Be

Medtronic (MDT) has undergone strategic shifts, exiting less profitable businesses and investing in new technology, leading to its highest annual revenue growth in a decade. Q1 fiscal 2027 saw a 13.7% revenue increase and earnings above guidance, prompting raised full-year forecasts. The stock has risen 15% in three months but remains 30% below its 2021 high, offering a high dividend yield.

fool.com2 min
SEP 8
$MDTMedAI 8/10

Down Stocks to Buy and Hold for the Next 10 Years

Medtronic (MDT) reported Q1 2027 revenue of $9.8B, up 13.7% YoY, and raised full-year guidance. Despite a 2% YTD decline, its long-term growth prospects and dividend history make it attractive. MercadoLibre (MELI) saw Q2 revenue rise 50% YoY to $10.2B but EPS fell due to investments. Its initiatives aim to strengthen its market position and moat.

aol.com3 min
SEP 8
$MDTHighAI 8/10

2 Beaten-Down Stocks to Buy and Hold for the Next 10 Years

Medtronic (NYSE:MDT) reported Q1 2027 revenue of $9.8B (+13.7% YoY) and raised guidance. Despite a 2% YTD decline, its long-term growth prospects and dividend history are noted. MercadoLibre (NASDAQ:MELI) saw Q2 revenue of $10.2B (+50% YoY) but lower EPS due to investments. Both companies are recommended as long-term holds.

yahoo.com3 min